Current Edition

eConsent: Tearing Down Barriers to Oncology Trials

Despite more people surviving cancer than ever before, a staggering 9.6 million people worldwide died from cancer in 20181, making the need for new drugs a global priority. With the search for new treatments stepping up, patient technology and systems that can improve recruitment and retention while contributing to the collection of cleaner, more compliant data are in demand. Bill Byrom et al. of Signant Health discuss how eConsent, when implemented well, has the potential to help companies rise to the challenge by removing some of the common barriers to clinical development.